MACROCYCLIC PURINES FOR THE TREATMENT OF VIRAL INFECTIONS

• US 20150299221A1
• Filed: 07/12/2013
• Published: 10/22/2015
• Est. Priority Date: 07/13/2012
• Status: Active Grant

• Current Assignee: Janssen Sciences Ireland Unlimited Company (Johnson & Johnson)
• Original Assignee: Janssen R&D Ireland (Johnson & Johnson)
• Inventors: Bonfanti, Jean-Francois, Fortin, Jerome Michel Claude, Muller, Philippe, Doublet, Frederic Marc Maurice, Raboisson, Pierre Jean-Marie Bernard, Arnoult, Eric Pierre Alexandre
• Granted Patent: US 10,280,180 B2
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07D 487/16 Peri-condensed systems
• CPC Class Codes: C07D 487/22 in which the condensed system contains four or more hetero rings
• CPC Class Codes: C07D 498/16 Peri-condensed systems
• CPC Class Codes: C07D 498/22 in which the condensed system contains four or more hetero rings

Abstract

This invention relates macrocyclic purine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.

Claims

1. A compound having formula (I)

3. A pharmaceutical composition comprising a compound having formula (I) or a pharmaceutically acceptable salt thereof according to claim 1 and one or more pharmaceutically acceptable excipients, diluents or carriers.

5. A method of treatment of a subject suffering from a disorder in which the modulation of TLR7 is involved, comprising administering to the subject a therapeutically effective amount of a compound having formula (I), or pharmaceutically acceptable salt thereof, as claimed in claim 1.

2. A compound selected from the group consisting of:

6. A pharmaceutical composition comprising a compound according to claim 2 and at least one pharmaceutically acceptable excipient, diluent and carrier.

7. A method of treatment of a subject suffering from a disorder in which the modulation of TLR7 is involved, comprising administering to the subject a therapeutically effective amount of a compound according to claim 2.

4. (canceled)